 STUDY OF RITUXIMAB-HCVAD ALTERNATING WITH RITUXIMAB-METHOTREXATE-CYTARABINE VERSUS STANDARD RITUXIMAB-CHOP EVERY 21 DAYS FOR PATIENTS WITH NEWLY DIAGNOSED HIGH RISK AGGRESSIVE B-CELL NON-HODGKINS LYMPHOMAS IN PATIENTS 60 YEARS OLD OR YOUNGER: 